Unsuspected risk factors of frequent exacerbations requiring hospital admission in chronic obstructive pulmonary disease

International Journal of Clinical Practice

Volumn 67, Issue 7, 2013, Pages 691-697

  Ozyilmaz, E ^a   Kokturk, N ^b   Teksut, G ^b   Tatlicioglu, T ^b  

^a CUKUROVA UNIVERSITY   (Turkey)

^b GAZI UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; THEOPHYLLINE;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EVALUATION; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; FORCED EXPIRATORY VOLUME; FUNCTIONAL STATUS; GASTROESOPHAGEAL REFLUX; HEMATOCRIT; HOSPITAL ADMISSION; HOSPITAL READMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTPATIENT CARE; OXYGEN THERAPY; PATIENT COMPLIANCE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR;

ACUTE DISEASE; ADMINISTRATION, INHALATION; AGED; FEMALE; GASTROESOPHAGEAL REFLUX; HOSPITALIZATION; HUMANS; MALE; MEDICATION ADHERENCE; PATIENT READMISSION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECURRENCE; RESPIRATORY FUNCTION TESTS; RISK FACTORS;

EID: 84879111667     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12150     Document Type: Article

References (35)

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management of chronic obstructive pulmonary disease. NHLBI/WHO workshop report 2006. Updated: November 2006. www.goldcopd.com/ workshop/index.html (accessed February 2007).
2. Anzueto A, Sethi S, Martinez FJ,. Exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2007; 4: 554-64.
3. Celli BR, Barnes PJ,. Exacerbations of chronic obstructive pulmonary disease. Eur Respir J 2007; 29: 1224-38.
4. Seemungal TAR, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA,. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161: 1608-13.
5. Seemungal TAR, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA,. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 1418-22.
6. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA,. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57: 847-52.
7. Paggiaro PL, Dahle R, Bakran I, Frith L, Hollingworth K, Efthimiou J,. Multicenter randomized placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group. Lancet 1998; 351: 773-80.
8. Miravittles M,. Do we need new antibiotics for treating exacerbations of COPD? Ther Adv Respir Dis 2007; 1: 61-76.
9. Foreman MG, DeMeo DL, Horsh CP, Reilly JJ, Silverman EK,. Clinical determinants of exacerbations in severe early-onset COPD. Eur Respir J 2007; 30: 1124-30.
10. Renom F, Yanez A, Garau M, et al. Prognosis of COPD patients requiring frequent hospitalization: role of airway infection. Respir Med 2010; 104: 840-8.
11. Donaldson GC, Wedzicha JA,. COPD exacerbations. 1: Epidemiology. Thorax 2006; 61: 164-8.
12. 1. Respir Med 2008; 102 (Suppl. 1): S27-35.
13. Burgel PR, Nesme-Meyer P, Chanez P, et al. Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects. Chest 2009; 135: 975-82.
14. Bahadori K, FitzGerald JM, Levy RD, Fera T, Swiston J,. Risk factors and outcomes associated with chronic obstructive pulmonary disease exacerbations requiring hospitalization. Can Respir J 2009; 16: e43-9.
15. Wedzicha JA, Seemungal TA,. COPD exacerbations: defining their cause and prevention. Lancet 2007; 370: 786-96.
16. Kitapcioglu G, Mandiracioglu A, Caymaz Bor C, Bor S,. Overlap syndromes of dyspepsia and gastro-oesophageal reflux in the community. Turk J Gastroenterol 2007; 18: 14-9.
17. Quanjer PH, Tammeling GJ, Cotes JE, et al. Lung volumes and forced ventilator flows. Report of the Working Party on Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl 1993; 16: 5-40.
18. Shorr AF, Doyle J, Stern L, Dolgitser M, Zilberberg MD,. Anemia in chronic obstructive pulmonary disease: epidemiology and economic implications. Curr Med Res Opin 2008; 24: 1123-30.
19. Weiss G, Goodnough LT,. Anemia in chronic diseases. N Engl J Med 2005; 352: 1011-23.
20. Similowski T, Agusti A, MacNee W, Schönhofer B,. The potential impact of anaemia of chronic disease in COPD. Eur Respir J 2006; 27: 390-6.
21. Chambellan A, Chailleux E, Similowski T,. Prognostic value of haematocrit in patients with severe COPD receiving long-term oxygen therapy. Chest 2005; 128: 1201-8.
22. Markoulaki D, Kostikas K, Papatheodorou G, et al. Haemoglobin, erythropoietin and systemic inflammation in exacerbations of chronic obstructive pulmonary disease. Eur J Intern Med 2011; 22: 103-7.
23. Boutou AK, Stanopoulos I, Pitsiou GG, et al. Anemia of chronic disease in chronic obstructive pulmonary disease: a case-control study of cardiopulmonary exercise responses. Respiration 2011; 82: 237-45.
24. Gullestad L, Aukrust P, Ueland T, et al. Effect of high-versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure. J Am Coll Cardiol 1999; 34: 2061-7.
25. Mancini GB, Etminan M, Zhang B, Levesque LE, FitzGerald JM, Brophy JM,. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors and, angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol 2006; 47: 2554-60.
26. Mortenson EM, Copeland LA, Pugh MY, et al. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir Res 2009; 10: 45.
27. Di Marco F, Guazzi M, Vicenzi M, et al. Effect of enalapril on exercise cardiopulmonary performance in chronic obstructive pulmonary disease: a pilot study. Pulm Pharmacol Ther 2010; 23: 159-64.
28. Kempainen RR, Savik K, Whelan TP, Dunitz JM, Herrington CS, Billings JL,. High prevalence of proximal and distal gastro-oesophageal reflux disease in advanced COPD. Chest 2007; 131: 1666-71.
29. Rascon-Aguilar IE, Pamer M, Wludyka P, et al. Role of gastro-oesophageal reflux symptoms in exacerbations of COPD. Chest 2006; 130: 1096-101.
30. Niklasson A, Strid H, Simrén M, Engström CP, Björnsson E,. Prevalence of gastrointestinal symptoms in patients with chronic obstructive pulmonary disease. Eur J Gastroenterol Hepatol 2008; 20: 335-41.
31. Hurst JR, Vestbo J, Anzueto A, et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010; 363: 1128-38.
32. Hurst JR, Donaldson GC, Quint JK, Goldring JJ, Baghai-Ravary R, Wedzicha JA,. Temporal clustering of exacerbations in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 179: 369-74.
33. Roberts CM, Lowe D, Bucknall CE, Ryland I, Kelly Y, Pearson MG,. Clinical audit indicators of outcome following admission to hospital with acute exacerbation of chronic obstructive pulmonary disease. Thorax 2002; 57: 137-41.
34. Tamura G, Ohta K,. Adherence to treatment by patients with asthma or COPD: comparison between inhaled drugs and transdermal patch. Respir Med 2007; 101: 1895-902.
35. Vestbo J, Anderson JA, Calverley PM, et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax 2009; 64: 839-43.